Showing results (51-60 of 332) with videos related to
Sort By:
Pageof 34
Biotechnology and Bioengineering|November 14, 2013
Co-regulation of primary mouse hepatocyte viability and function by oxygen and matrixLorenna D Buck, S Walker Inman, Ivan Rusyn, et al.Environmental Science & Technology|June 12, 2026
Probabilistic Concentration-Response Modeling and Risk Prioritization of Defined Mixtures of PFAS Using Human In Vitro AssaysLucie C Ford, Hsing-Chieh Lin, Weihsueh A Chiu, et al.The Science of the Total Environment|May 29, 2025
An approach to uncover significant direct and mediated relationships in multi-dimensional new approach methods (NAMs) data: A case study of hazard evaluation of petroleum UVCBsYi-Hui Zhou, Paul J Gallins, Ivan Rusyn, et al.Expert Opinion on Drug Metabolism & Toxicology|February 22, 2021
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterizationSarah D Burnett, Alexander D Blanchette, Weihsueh A Chiu, et al.Journal of Pharmacological and Toxicological Methods|January 9, 2022
A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variabilityAlexander D Blanchette, Sarah D Burnett, Ivan Rusyn, et al.Mutation Research. Reviews in Mutation Research|December 9, 2014
Trichloroethylene biotransformation and its role in mutagenicity, carcinogenicity and target organ toxicityLawrence H Lash, Weihsueh A Chiu, Kathryn Z Guyton, et al.Toxicological Sciences : an Official Journal of the Society of Toxicology|February 11, 2020
In Vitro Bioavailability of the Hydrocarbon Fractions of Dimethyl Sulfoxide Extracts of Petroleum SubstancesYu-Syuan Luo, Kyle C Ferguson, Ivan Rusyn, et al.Toxicology Research|March 16, 2013
In vitro models for liver toxicity testingValerie Y Soldatow, Edward L Lecluyse, Linda G Griffith, et al.Assay and Drug Development Technologies|November 6, 2015
High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and HepatocytesFabian Alexander Grimm, Yasuhiro Iwata, Oksana Sirenko, et al.Risk Analysis : an Official Publication of the Society for Risk Analysis|August 16, 2024
Reducing uncertainty in dose-response assessments by incorporating Bayesian benchmark dose modeling and in vitro data on population variabilityEn-Hsuan Lu, Lucie C Ford, Ivan Rusyn, et al.Pageof 34